The FDA's positive feedback is a significant milestone for Pasithea Therapeutics, as it allows the company to proceed with patient dosing in its clinical trials for PAS-004. This step is crucial for advancing the treatment through the regulatory pathway and potentially bringing it to market. The orphan drug designation also adds to the positive outlook, as it provides certain benefits that can accelerate development. Investors may view this news as a strong indicator of progress and potential, likely leading to a positive short-term impact on KTTA's stock price.